Neurology and Neurosurgery

17-32 of 38

• 

  RestartResume

  The 2-Point Signal: Apply ≥2-Point Rule

  RestartResume

  The 2-Point Signal: Apply ≥2-Point Rule

  MinuteCE®

  The 2-Point Signal: Apply ≥2-Point Rule

  Christyn Edmundson, MD; Gil I. Wolfe MD, FAAN

  1.00 program credit

  • 

    

    Christyn Edmundson, MD

  • 

    

    Gil I. Wolfe MD, FAAN

  1.00 program credit

• 

  RestartResume

  FcRn: Same Class, Different Paths—Spot Agent Differentiators

  RestartResume

  FcRn: Same Class, Different Paths—Spot Agent Differentiators

  MinuteCE®

  FcRn: Same Class, Different Paths—Spot Agent Differentiators

  Christyn Edmundson, MD; Gil I. Wolfe MD, FAAN

  1.00 program credit

  • 

    

    Christyn Edmundson, MD

  • 

    

    Gil I. Wolfe MD, FAAN

  1.00 program credit

• 

  RestartResume

  The IgG Clock: Redose Using IgG Kinetics

  RestartResume

  The IgG Clock: Redose Using IgG Kinetics

  MinuteCE®

  The IgG Clock: Redose Using IgG Kinetics

  Christyn Edmundson, MD; Gil I. Wolfe MD, FAAN

  1.00 program credit

  • 

    

    Christyn Edmundson, MD

  • 

    

    Gil I. Wolfe MD, FAAN

  1.00 program credit

• 

  RestartResume

  Scorecards That Matter: Use MG-ADL, MG-MMT, QMG, QoL

  RestartResume

  Scorecards That Matter: Use MG-ADL, MG-MMT, QMG, QoL

  MinuteCE®

  Scorecards That Matter: Use MG-ADL, MG-MMT, QMG, QoL

  Christyn Edmundson, MD

  1.00 program credit

  • 

    

    Christyn Edmundson, MD

  1.00 program credit

• 

  RestartResume

  Mechanism-Driven gMG Therapy: FcRn Antagonists and the Rise of Precision Neurology

  RestartResume

  Mechanism-Driven gMG Therapy: FcRn Antagonists and the Rise of Precision Neurology

  CME/CE

  Mechanism-Driven gMG Therapy: FcRn Antagonists and the Rise of Precision Neurology

  Neelam Goyal, MD; Christyn Edmundson, MD

  0.50 credits

  • 

    

    Neelam Goyal, MD

  • 

    

    Christyn Edmundson, MD

  0.50 credits

• 

  RestartResume

  Treatment Advances in Generalized Myasthenia Gravis: A Pathophysiology-Driven Framework Leveraging FcRn Therapeutics

  RestartResume

  Treatment Advances in Generalized Myasthenia Gravis: A Pathophysiology-Driven Framework Leveraging FcRn Therapeutics

  CME/CE

  Treatment Advances in Generalized Myasthenia Gravis: A Pathophysiology-Driven Framework Leveraging FcRn Therapeutics

  Vera Bril, MD; Neelam Goyal, MD

  0.75 credits

  • 

    

    Vera Bril, MD

  • 

    

    Neelam Goyal, MD

  0.75 credits

• 

  RestartResume

  Managing Side Effects in FcRn Therapy: Best Practices for gMG

  RestartResume

  Managing Side Effects in FcRn Therapy: Best Practices for gMG

  MinuteCE®

  Managing Side Effects in FcRn Therapy: Best Practices for gMG

  Vera Bril, MD; Nicholas J. Silvestri, MD

  1.00 program credit

  • 

    

    Vera Bril, MD

  • 

    

    Nicholas J. Silvestri, MD

  1.00 program credit

• 

  RestartResume

  Autoantibodies Explained: Anti-AChR, Anti-MuSK, and Their Diagnostic Role

  RestartResume

  Autoantibodies Explained: Anti-AChR, Anti-MuSK, and Their Diagnostic Role

  MinuteCE®

  Autoantibodies Explained: Anti-AChR, Anti-MuSK, and Their Diagnostic Role

  Vera Bril, MD; Nicholas J. Silvestri, MD

  1.00 program credit

  • 

    

    Vera Bril, MD

  • 

    

    Nicholas J. Silvestri, MD

  1.00 program credit

• 

  RestartResume

  Ocular to Generalized MG: How and Why the Disease Evolves

  RestartResume

  Ocular to Generalized MG: How and Why the Disease Evolves

  MinuteCE®

  Ocular to Generalized MG: How and Why the Disease Evolves

  Vera Bril, MD; Hans Katzberg, MD

  1.00 program credit

  • 

    

    Vera Bril, MD

  • 

    

    Hans Katzberg, MD

  1.00 program credit

• 

  RestartResume

  Treatment Advances in Generalized Myasthenia Gravis: Clinical and Laboratory Criteria for Diagnosis and Optimal Treatment Selection

  RestartResume

  Treatment Advances in Generalized Myasthenia Gravis: Clinical and Laboratory Criteria for Diagnosis and Optimal Treatment Selection

  CME/CE

  Treatment Advances in Generalized Myasthenia Gravis: Clinical and Laboratory Criteria for Diagnosis and Optimal Treatment Selection

  Vera Bril, MD; Jonathan Strober, MD

  0.75 credits

  • 

    

    Vera Bril, MD

  • 

    

    Jonathan Strober, MD

  0.75 credits

• 

  MinuteCE®

  Treatment Advances in Generalized Myasthenia Gravis: Addressing the Nuances of its Underlying Immunopathology

  Vera Bril, MD; Nicholas J. Silvestri, MD

  1.00 credit 10 episodes

  • 

    

    Vera Bril, MD

  • 

    

    Nicholas J. Silvestri, MD

  • 

    

    Hans Katzberg, MD

  1.00 credit 10 episodes

• 

  RestartResume

  A Scientific Look at FcRn Antagonists: Mechanisms of Action Explained

  RestartResume

  A Scientific Look at FcRn Antagonists: Mechanisms of Action Explained

  MinuteCE®

  A Scientific Look at FcRn Antagonists: Mechanisms of Action Explained

  Vera Bril, MD; Nicholas J. Silvestri, MD

  1.00 program credit

  • 

    

    Vera Bril, MD

  • 

    

    Nicholas J. Silvestri, MD

  1.00 program credit

• 

  RestartResume

  New Frontiers in MG: How FcRn Antagonists Are Changing MG Therapy

  RestartResume

  New Frontiers in MG: How FcRn Antagonists Are Changing MG Therapy

  MinuteCE®

  New Frontiers in MG: How FcRn Antagonists Are Changing MG Therapy

  Vera Bril, MD; Nicholas J. Silvestri, MD

  1.00 program credit

  • 

    

    Vera Bril, MD

  • 

    

    Nicholas J. Silvestri, MD

  1.00 program credit

• 

  RestartResume

  Preventing Myasthenic Crisis: Early Signs and Critical Interventions

  RestartResume

  Preventing Myasthenic Crisis: Early Signs and Critical Interventions

  MinuteCE®

  Preventing Myasthenic Crisis: Early Signs and Critical Interventions

  Vera Bril, MD; Hans Katzberg, MD

  1.00 program credit

  • 

    

    Vera Bril, MD

  • 

    

    Hans Katzberg, MD

  1.00 program credit

• 

  RestartResume

  Precision Medicine for gMG: Tailoring Treatments Based on Patient Profiles

  RestartResume

  Precision Medicine for gMG: Tailoring Treatments Based on Patient Profiles

  MinuteCE®

  Precision Medicine for gMG: Tailoring Treatments Based on Patient Profiles

  Vera Bril, MD; Nicholas J. Silvestri, MD

  1.00 program credit

  • 

    

    Vera Bril, MD

  • 

    

    Nicholas J. Silvestri, MD

  1.00 program credit

• 

  RestartResume

  Traditional MG Treatments: Balancing Benefits, Risks, and Side Effect Management

  RestartResume

  Traditional MG Treatments: Balancing Benefits, Risks, and Side Effect Management

  MinuteCE®

  Traditional MG Treatments: Balancing Benefits, Risks, and Side Effect Management

  Vera Bril, MD; Hans Katzberg, MD

  1.00 program credit

  • 

    

    Vera Bril, MD

  • 

    

    Hans Katzberg, MD

  1.00 program credit

• Previous
• 1
• 2
• 3
• Next